Brief: 60 Degrees Pharmaceuticals Enrolls First Patient In Tafenoquine Expanded Access Clinical Study
08/01/2025 14:07
Jan 8 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMACEUTICALS ENROLLS FIRST PATIENT IN
TAFENOQUINE
EXPANDED ACCESS CLINICAL STUDY FOR PERSISTENT (B. MICROTI)
BABESIOSIS
Source text: urn:newsml:reuters.com:*:nGNX8gHCyr
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM